

MERGER ANNOUNCEMENT 22 JANUARY 2013

Competition Authority clears the acquisition of Kent Pharmaceuticals

The Competition Authority has cleared the proposed transaction whereby DCC plc would acquire sole control of Kent Pharmaceuticals (Holdings) Limited. The transaction was notified by the parties under the Competition Act 2002 on 27 December 2012.

The Authority has formed the view that the proposed transaction will not lead to a substantial lessening of competition in any markets for goods or services in the State. The Authority will publish a public version of the reasons for its determination on its website (www.tca.ie) no later than 21 March 2013 after allowing the parties the opportunity to request that confidential information is removed from the published version.

Notes

DCC plc is an Irish registered public company listed on the Irish and the London stock exchanges and headquartered in Dublin. DCC is active globally and within the State through five business divisions including DCC Healthcare, the division of greatest relevance to this acquisition. DCC plc's other four divisions are:

- DCC Energy involved in the sales, marketing and distribution of oil/fuel products, and liquid petroleum gas.
- DCC SerCom involved in information technology, communications and home entertainment products sales, marketing and also distribution and supply chain management services.
- DCC Environmental involved in the provision of waste management and recycling services to commercial, industrial and public sector customers.
- DCC Food & Beverage involved in food and beverage sales, marketing and distribution.

Kent Pharmaceuticals (Holdings) Limited is a private UK-based company active in the manufacture and supply of pharmaceutical products, in particular generic beta lactam antibiotics (e.g., penicillin).

For further information contact:

Clodagh Coffey, Communications Manager, The Competition Authority Tel: 01 8045406 Mobile: 087 915 5406 email: cc@tca.ie



Kent Pharmaceuticals (Holdings) Limited operates primarily through its manufacturing subsidiary Athlone Pharmaceuticals Limited, and two distribution subsidiaries Kent Pharmaceuticals Limited (in the UK) and GAP Pharma (in Ireland).